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Dear editor
While updating our Cochrane review on tapentadol for chronic musculoskeletal pain,1 
we found a study by Ueberall and Mueller-Schwefe.2 It passed the initial screening phase 
by using words such as “blinded” and “randomly”, methodologically positive charac-
teristics most often seen in randomized controlled trials (RCTs). On further analysis, 
we found that it is not an RCT and therefore not eligible for our Cochrane review. 
We nonetheless remained interested, since the authors clearly made methodological 
options that, despite sounding pondered, rigorous, and methodologically desirable, in 
fact add little to nothing in terms of quality or rigor. In fact, this quasi-rigor can be 
fully appreciated when assessing the study using the Cochrane model for risk of bias 
in non-randomized studies of interventions.3
We consider that the decision to randomize was key to the overall assessment of 
this study. What the authors did was randomly select which participants were going to 
be studied, and which would not. What may have been expected is to randomly allocate 
participants to treatment with either tapentadol or oxycodone, as is done in an RCT.
We believe that the risk of bias due to confounding is moderate. Although all impor-
tant confounding domains were appropriately measured and controlled for, we would 
still expect some degree of confounding, as is the case for most observational research.
The bias stemming from classification is low, since the intervention status is well 
defined. Also, the risk of bias due to deviations from the intended interventions (also 
called performance bias) is low, since any deviations would reflect usual practice of 
neurologists, and for this the authors should be commended.
Importantly, the attrition rates in this study were similar in the tapentadol and oxy-
codone groups (22.6% vs. 23.4%, respectively), unlike what was found in other relevant 
studies.4 Overall, the bias due to missing data (also called attrition bias) was low.
The bias due to measurement in outcomes is another cause for serious concern, since 
the outcome measures in this study were subjective, and both the study participants and 
researchers knew who was receiving tapentadol and who was receiving oxycodone.
Finally, the bias due to selection of the reported results is moderate, since we are 
not aware of a publically available study protocol, despite the fact that the outcomes 
studied are internally and externally consistent.
Overall, in our opinion, this study is at a serious risk of bias, meaning that it has 
important methodological problems, and that the results should be put into the context 
Correspondence: João Costa
Laboratório de Farmacologia Clínica 
e terapêutica, Faculdade de Medicina, 
Universidade de Lisboa, Avenida 
Professor egas Moniz, 1649-028, 
Lisboa, Portugal
email jncosta@medicina.ulisboa.pt




Running head verso: Duarte et al
Running head recto: Response to the publication by Ueberall and Mueller-Schwefe
DOI: http://dx.doi.org/10.2147/JPR.S135619





of its biases. The risk of bias in measurement of outcomes 
(also called detection bias) will nearly always be problematic 
for any study in the area of pain research, since the outcomes 
are mostly very subjective and blinding of participants is 
very difficult. What is not commonly seen, in any field of 
research, is the author’s choice to artificially select a subset 
of participants to study, with no apparent reason for doing 
so. The choice to do so gravely undermines a study that 
would otherwise have been more informative, as in the case 
of a true RCT.
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Dear editor
Thank you for the opportunity to reply to the letter of Duarte 
et al and to discuss their objections concerning our analysis 
of data from the German Pain Registry.
As described in our publication,1 the data for our analy-
sis were not prospectively gathered during a double-blind 
randomized controlled trial (RCT), but retrospectively taken 
from the German Pain registry – a large database that provides 
detailed data (based on validated patient questionnaires and 
physician-recorded information, etc.) on the routine treatment 
of pain patients for health care research purposes. Patients 
with low back pain with a neuropathic component in whom 
a new treatment with either oxycodone/naloxone or tapent-
adol was initiated within a specific period were identified by 
predefined inclusion and exclusion criteria (as described in 
our paper). From patients who fulfilled the enrollment criteria 
for analysis, we took a random sample (based on an a priori 
defined randomization list) to guarantee an unbiased data 
selection for analysis and evaluated the effects of both treat-
ments over a 12-week observation period in a blinded fashion.
As Duarte et al wrote, this process has some risk for a 
selection bias and therefore we performed a complementary 
analysis comparing the baseline characteristics of those 
patients whose data were selected vs. those whose data were 
not selected (section “Randomization effects” in our paper) 
and found only minor and insignificant between-group dif-
ferences (also for the outcome data).
We have chosen this special kind of data analysis, because 
we were not interested in another replication of scientific 
RCT data but interested in those reflecting the efficiency 
of both drugs under real-life conditions, where the decision 
for treatment is neither dictated by distinct inclusion and 
exclusion criteria nor a random list, but only by individual 
patient needs and the intention of a physician to prescribe 
the most appropriate treatment available. In addition to that, 
treatments were tailored and maintained according to the spe-
cific responses of the individuals treated and this obviously 
resulted in significant differences with respect to distinct 
outcome parameters and endpoint analyses vs. those of the 
RCTs mentioned by Duarte et al (especially the attrition rates 
of patients on treatment), as we have discussed extensively 
in our paper.
Due to the fact that our analyses were based on routine 
data documented during routine practice under daily life 
conditions (sampled primarily for the purpose to document 
the response of a patient to a specific pharmacological treat-
ment), physicians and patients of course knew what kind 
of treatment has been given. However, statistical analyses 
were done in a blinded fashion (i.e., without any knowl-
edge on the drug status of distinct patients) to guarantee 
unbiased results.
For these (and a number of further) reasons, we strongly 
disagree with the conclusion by Duarte et al about the meth-
odological shortcomings of our work and the allegation of a 
“serious risk of bias”. In contrast to those RCTs, the members 
of the Cochrane group usually prefer our approach focused on 
routine data of real-life treatments performed to improve the 
suffering of individual patients. Patient selection, procedures/
treatments, and biometrical strategies were transparently 
reported and data of both comparators were equally handled, 
minimizing the risk of a positive discrimination of one treat-
ment vs. the other. Finally, the subsets of patient data analyzed 
were randomly selected not to increase but to reduce the risk 
of bias, and our own analyses to prove this concept provided 
no signal that this approach failed.
We believe that this kind of analysis has not only the 
potential to complement the reports from conventional RCTs 
but also to overcome their obvious shortcomings. We strongly 
believe in the concept of RCTs for regulatory and approval 
purposes, but we (along with many other practitioners) are 
increasingly afflicted by doubts that if RCTs (at least the way 
they are realized today) are of any help to answer the question 
which kind of treatment works best for individual patients 
under real-life conditions and which size/kind of effect can 
be achieved. To gain further insight into the real-life effects 
of analgesic drug treatments, new and alternative health care 
research approaches are therefore necessary. If our approach 
and the current controversy of its pros and cons help to 
promote a sincere discussion regarding the best strategy for 
future patient-centered studies, we have achieved our main 
objective and we thank all our colleagues who have helped 
us on this way.
Journal of Pain Research  2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Journal of Pain Research 
Publish your work in this journal
Submit your manuscript here:  https://www.dovepress.com/journal-of-pain-research-journal 
The Journal of Pain Research is an international, peer reviewed, open 
access, online journal that welcomes laboratory and clinical findings 
in the fields of pain research and the prevention and management 
of pain. Original research, reviews, symposium reports, hypoth-
esis formation and commentaries are all considered for publication. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 






MAU and GHHM-S are physicians and independent of any 
significant/relevant financial or other relationship to the 
sponsor, except for minor reimbursements for occasional 
lecture or consulting fees. Both are honorary members of the 
management boards of the German Pain Association and the 
German Pain League. The German Pain Registry is hosted 
by an independent contract research organization by order 
of the German Pain Association and under the control of the 
Institute of Neurological Sciences and collects standardized 
data from daily routine medical care since January 2000. 
 During the last 2 years, MAU received financial support and/
or expenses in form of research money, consultancy fees, and/
or remunerations for lecture activities from Almirall, Archi-
medes, Grünenthal, Kyowa Kirin, Menarini, MSD, Mucos, 
Mundipharma, Pfizer, Pharm-Allergan, Shionoghi, and 
TEVA. During the last 2 years, GHHM-S received financial 
support and/or expenses in form of research money, consul-
tancy fees, and/or remunerations for lecture activities from 
Allergan, Almirall, Grünenthal, Kyowa Kirin, Mundipharma, 
Pf izer, Pharm-Allergan, Shionoghi, and TEVA. The authors 
report no other conflicts of interest in this communication.
Dove Medical Press encourages responsible, free and frank academic debate. The content of the Journal of Pain Research ‘letters to the editor’ section does not necessarily represent the 
views of Dove Medical Press, its officers, agents, employees, related entities or the Journal of Pain Research editors. While all reasonable steps have been taken to confirm the content of each 
letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.
Reference
1. Ueberall MA, Mueller-Schwefe GH. Efficacy and tolerability balance 
of oxycodone/naloxone and tapentadol in chronic low back pain with a 
neuropathic component: a blinded end point analysis of randomly selected 
routine data from 12-week prospective open-label observations. J Pain 
Res. 2016;9:1001–1020.
